24,25(OH)2D3, bone formation, and bone resorption in vitamin D-deficient, azotemic rats.
Bone formation, mineralization, and resorption were measured in vitamin D-deficient, azotemic rats given two different dosages of 24,25(OH)2D3 daily and in vehicle-treated controls (C). The intraperitoneal administration of 65 pmol over a 10 day period corrected the hypocalcemia observed in C, whereas 130 pmol produced mild hypercalcemia. Both dosages reduced osteoid width, osteoid area, and mineralization front width from control values. The rates of bone and matrix formation were unaffected by treatment. In C, matrix formation exceeded bone formation and resulted in osteoid accumulation; both dosages of 24,25(OH)2D3 reversed this relationship such that bone formation exceeded matrix formation in each treatment group. The rates of osteoid maturation and initial mineralization increased during repletion with 24,25(OH)2D3 at both dosage levels. However, the serum calcium concentration was correlated with both osteoid maturation rate (r = 0.68, P less than 0.01) and initial mineralization rate (r = 0.63, P less than 0.01) when all three experimental groups were considered. Bone resorption was unchanged from control values during treatment with 24,25(OH)2D3. The results suggest that 24,25(OH)2D3 promotes the maturation and mineralization of osteoid, and that this metabolite differs in its effects on bone formation and resorption. It is not clear, however, that the changes in bone dynamics observed are independent of the calcemic response induced by metabolite repletion under the conditions of this experiment.
D015650:24,25-Dihydroxyvitamin D 3; D000818:Animals; D001806:Blood Urea Nitrogen; D001835:Body Weight; D001846:Bone Development / Q000187:drug effects*; D001857:Bone Matrix / Q000187:drug effects; D001862:Bone Resorption / Q000187:drug effects*; D001842:Bone and Bones / Q000473:pathology; D002118:Calcium / Q000097:blood; D004100:Dihydroxycholecalciferols / Q000008:administration & dosage / Q000494:pharmacology*; D007274:Injections, Intraperitoneal; D008297:Male; D010012:Osteogenesis / Q000187:drug effects*; D010758:Phosphorus / Q000097:blood; D051381:Rats; D014808:Vitamin D Deficiency / Q000473:pathology / Q000503:physiopathology*
D004100:Dihydroxycholecalciferols; D010758:Phosphorus; D015650:24,25-Dihydroxyvitamin D 3; D002118:Calcium